| Entry |
|
|---|
| Name |
Adalimumab (USAN/INN);
Adalimumab (genetical recombination) (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 1] (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 2] (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 3] (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 4] (JAN);
Adalimumab-adaz;
Adalimumab-adbm;
Adalimumab-afzb;
Adalimumab-atto;
Adalimumab-bwwd;
Adalimumab-fkjp;
Adalimumab-aaty;
Adalimumab-aacf;
Adalimumab-aqvh;
Adalimumab-ryvk;
Humira (TN);
Abrilada (TN);
Amjevita (TN);
Cyltezo (TN);
Hadlima (TN);
Hyrimoz (TN) |
|---|
| Product |
ABRILADA (Pfizer Laboratories Div Pfizer), ABRILADA (Pfizer Laboratories Div Pfizer), ADALIMUMAB (Biocon Biologics), ADALIMUMAB (CELLTRION USA), ADALIMUMAB (Golden State Medical Supply), ADALIMUMAB (Mylan Specialty L.P.), ADALIMUMAB (Sandoz), ADALIMUMAB-AACF (Fresenius Kabi USA), ADALIMUMAB-ADBM (Boehringer Ingelheim Pharmaceuticals), ADALIMUMAB-ADBM (QUALLENT PHARMACEUTICALS HEALTH LLC), ADALIMUMAB-RYVK (Quallent Pharmaceuticals Health LLC), AMJEVITA (A-S Medication Solutions), AMJEVITA (A-S Medication Solutions), AMJEVITA (Amgen USA), AMJEVITA (Amgen), AMJEVITA (Optum Health Solutions (Ireland) Limited), CYLTEZO (Boehringer Ingelheim Pharmaceuticals), HADLIMA (A-S Medication Solutions), HADLIMA (A-S Medication Solutions), HADLIMA (A-S Medication Solutions), HADLIMA (A-S Medication Solutions), HADLIMA (Organon LLC), HULIO (Biocon Biologics), HULIO (Mylan Specialty L.P.), HUMIRA (A-S Medication Solutions), HUMIRA (AbbVie), HUMIRA (Cordavis Limited), HYRIMOZ (Cordavis Limited), HYRIMOZ (Sandoz), IDACIO (Fresenius Kabi USA), SIMLANDI (Teva Pharmaceuticals USA), YUFLYMA (CELLTRION USA), YUSIMRY (Coherus BioSciences), YUSIMRY (Meitheal Pharmaceuticals) |
|---|
| Sequence |
(Heavy chain)
EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYAMHWVRQA PGKGLEWVSA ITWNSGHIDY
ADSVEGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAKVS YLSTASSLDY WGQGTLVTVS
SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRD
ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR
WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCRASQGIR NYLAWYQQKP GKAPKLLIYA ASTLQSGVPS
RFSGSGSGTD FTLTISSLQP EDVATYYCQR YNRAPYTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H148-H204, H224-L214, H230-H'230, H233-H'233, H265-H325, H371-H429, H'22-H'96, H'148-H'204, H'224-L'214, H'265-H'325, H'371-H'429, L23-L88, L134-L194, L'23-L'88, L'134-L'194) |
|---|
| Type |
Peptide |
|---|
| Class |
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor
|
|---|
| Remark |
| Therapeutic category: | 3999 |
|
|---|
| Efficacy |
Anti-inflammatory, Antirheumatic, Anti-TNF-alpha antibody |
|---|
| Disease |
Rheumatoid arthritis [DS: H00630] Juvenile idiopathic arthritis [DS: H01672] Psoriatic arthritis [DS: H01507] Ankylosing spondylitis [DS: H01674] Adult Crohn's disease [DS: H00286] Pediatric Crohn's disease [DS: H00286] Ulcerative colitis [DS: H01466] Plaque psoriasis [DS: H01656] Hidradenitis suppurativa [DS: H00681] |
|---|
| Type |
Monoclonal antibody |
|---|
| Target |
|
|---|
| Pathway |
| hsa04060 | Cytokine-cytokine receptor interaction |
| hsa04612 | Antigen processing and presentation |
| hsa04650 | Natural killer cell mediated cytotoxicity |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07050 | Antirheumatics - DMARDs and biological agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
L04AB04 Adalimumab
D02597 Adalimumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunosuppressants
Tumor Necrosis Factor (TNF) Blockers
Adalimumab
D02597 Adalimumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D02597 Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 1] (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 2] (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 3] (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 4] (JAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor
D02597 Adalimumab
Drug classes [BR:br08332]
Immunological agent
DG01936 TNF inhibitor
D02597 Adalimumab
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D02597 Adalimumab
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Tumor necrosis factors
TNF (TNFA, TNFSF2)
D02597 Adalimumab (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02597
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D02597
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
|